Iovance's TIL therapy makes early headway in lung cancer; Antios and Arbutus join hands on HBV combo treatment
Iovance has posted a first look at its tumor infiltrating lymphocytes as a treatment for non-small cell lung cancer, paving the way for a pivotal study.
Among 28 patients enrolled in Cohort 3B of the IOV-COM-202 basket study — 24 of whom were evaluable — investigators recorded an overall response rate of 21.4% at the interim, with 1 complete response and 5 partial responses. All patients in the group had progressed on prior immune checkpoint inhibitor therapy, and some had received tyrosine kinase inhibitors. The six responders also underwent chemotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
